Clinical trials: Metastatic Transitional Cell Carcinoma
Urinary Bladder Neoplasm, Neoplasm Metastasis
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or…
- Trial name
- PIVOT-10 (NCT03785925)
- Testing
- Bempegaldesleukin, Nivolumab
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 192 people
- Sponsor
- Nektar Therapeutics
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well vorinostat works in treating patients with locally recurrent or metastatic cancer of…
- Conditions
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00363883
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma Associated 1 RNA, Human
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
The purpose of this study is to determine the efficacy and safety of pembrolizumab (pembro, MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder…
- Trial name
- NCT02853305
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Volunteers
- 1,010 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00112671
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma (UC)
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
This multicenter phase II trial will evaluate palbociclib (PD-0332991) in patients with metastatic urothelial carcinoma (UC) with cyclin-dependent kinase inhibitor 2A (CDKN2A) (also referred to as p16) loss and positive…
- Trial name
- NCT02334527
- Testing
- Palbociclib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
This phase II trial is studying how well giving gemcitabine, paclitaxel, and doxorubicin together with pegfilgrastim works in treating patients with metastatic or unresectable bladder cancer or urinary tract cancer and kidney…
- Conditions
- Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT00478361
- Testing
- Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Locally Advanced or Metastatic Urothelial Carcinoma
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
- Trial name
- NCT05327530
- Testing
- Avelumab, Sacituzumab Govitecan (SG), M6223
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 256 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Breast Cancer, Urothelial Carcinoma
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
This is a study of trastuzumab deruxtecan for the treatment of HER2-positive unresectable or metastatic breast cancer following two or more prior anti-HER2 based regimens.
- Trial name
- NCT03523572
- Testing
- Trastuzumab deruxtecan, Nivolumab
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has…
- Conditions
- Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT00942331
- Testing
- Bevacizumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- 873 sites in United States, Puerto Rico
- Volunteers
- 506 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT03047213
- Testing
- Sapanisertib
- Where
- 20 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Carcinoma, Transitional Cell
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder.
- Trial name
- NCT04039867
- Testing
- Oxaliplatin with Gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Irvine
Urothelial Carcinoma, Ureteral Neoplasms
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Background: Urothelial cancer (tumors of the bladder, urethra, ureter, or renal pelvis) often responds initially to standard chemotherapy treatments, but frequently recurs and can often spread to other parts of the body.
- Conditions
- Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral
- Trial name
- NCT01328574
- Testing
- TRC105
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Transitional Cell, Bladder Cancer
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer.
- Conditions
- Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
- Trial name
- NCT00722553
- Testing
- Pralatrexate Injection, Vitamin B12, Folic Acid
- Where
- 19 sites in United States, Argentina and 4 more
- Volunteers
- 30 people
- Sponsor
- Acrotech Biopharma Inc.
Urothelial Carcinoma
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Gemcitabine plus cisplatin is standard treatment for advanced urothelial cancer. Ipilimumab has shown intriguing activity as neoadjuvant therapy in patients with clinically localized bladder cancer undergoing radical cystectomy.
- Trial name
- NCT01524991
- Testing
- Gemcitabine, Cisplatin, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Hoosier Cancer Research Network
Bladder Cancer
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
Cisplatin is a very important agent for the treatment of TCC as it has a single agent response rate of approximately 15%. However, it has been most important as a part of combination chemotherapy, MVAC initially and now in…
- Trial name
- NCT00234494
- Testing
- Cisplatin, Gemcitabine, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Christopher Sweeney, MBBS
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
This phase Ib/II trial finds the best dose of selinexor and its effect with pembrolizumab in treating patients with urothelial carcinoma that are not eligible to receive the chemotherapy drug cisplatin, or have been given…
- Conditions
- Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma
- Trial name
- NCT04856189
- Testing
- Pembrolizumab, Selinexor
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mamta Parikh